Format

Send to

Choose Destination
Am J Cardiol. 2017 May 1;119(9):1382-1386. doi: 10.1016/j.amjcard.2017.01.040. Epub 2017 Feb 10.

Effects of Alpha Lipoic Acid on Multiple Cytokines and Biomarkers and Recurrence of Atrial Fibrillation Within 1 Year of Catheter Ablation.

Author information

1
Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Naples, Italy; Arrhythmias and Electrophysiology Department, John Paul II Research Foundation, Campobasso, Italy.
2
Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy; New York Presbyterian Hospital, Columbia University Medical Center, New York, New York. Electronic address: gsantulli001@gmail.com.
3
Arrhythmias and Electrophysiology Department, John Paul II Research Foundation, Campobasso, Italy.
4
Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Naples, Italy.

Abstract

Catheter ablation (CA) is a procedure commonly used to restore sinus rhythm in patients with atrial fibrillation (AF). However, AF recurrence after CA remains a relevant clinical issue. We tested the effects of an oral antioxidant treatment (alpha lipoic acid [ALA]) on AF recurrence post-CA. Patients with paroxysmal AF have been enrolled in a randomized, prospective, double-blind, controlled placebo trial. After CA, patients have been randomly assigned to receive ALA oral supplementation (ALA group) or placebo (control group) and evaluated at baseline and after a 12-month follow-up: 73 patients completed the 12-month follow-up (ALA: 33 and control: 40). No significant difference has been detected between the 2 groups at baseline. Strikingly, 1 year after CA, ALA therapy significantly reduced serum markers of inflammation. However, there was no significant difference in AF recurrence events at follow-up comparing ALA with placebo group. Multivariate analysis revealed that the only independent prognostic risk factor for AF recurrence after CA is age. In conclusion, ALA therapy reduces serum levels of common markers of inflammation in ablated patients. Nevertheless, ALA does not prevent AF recurrence after an ablative treatment.

PMID:
28258730
PMCID:
PMC5392151
DOI:
10.1016/j.amjcard.2017.01.040
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center